Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
-3.30 (-2.00%)
5:16:58 PM EDT: $161.70 -0.22 (-0.14%)

FDA Approved Rybrevant As First Treatment For Adult Patients With Non-Small Cell Lung Cancer

Published: 05/21/2021 16:41 GMT
Johnson & Johnson (JNJ) - FDA Approves First Targeted Therapy for Subset of Non-small Cell Lung Cancer.
Approved Rybrevant (amivantamab-vmjw) As First Treatment for Adult Patients With Non-small Cell Lung Cancer.
Granted Approval of Rybrevant to Janssen Pharmaceutical Companies of Johnson & Johnson.
Also Approved Guardant360 Cdx (guardant Health Inc.) As a Companion Diagnostic for Rybrevant Today.